Rapport Therapeutics, Inc. Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount
Rapport Therapeutics, Inc. (RAPP) reported Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount of 5.61 million shares for the 12-month period ending 2024-12-31, per its 10-K filed 2025-03-11.
Financial Statements › Income Statement › Earnings Per Share
us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount · last filed 2025-03-11
- Rapport Therapeutics, Inc. antidilutive securities excluded from computation of earnings per share, amount for fiscal 2024 was 5.61M shares, a 73.66% decline from fiscal 2023.
- Rapport Therapeutics, Inc. antidilutive securities excluded from computation of earnings per share, amount for fiscal 2023 was 21.30M shares.
| Period end | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 12 month |
|---|---|
| 2024-12-31 | 5.61M shares 10-K · filed 2025-03-11 |
| 2023-12-31 | 21.30M shares 10-K · filed 2025-03-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |
| Xeris Biopharma Holdings, Inc. (XERS) | United States | $1.632B | -80.10 |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| ANAPTYSBIO, INC (ANAB) | United States | $1.546B | -60.20 |
| Eton Pharmaceuticals, Inc. (ETON) | United States | $1.701B | 80.74 |
| Innoviva, Inc. (INVA) | United States | $1.493B | 4.62 |
| ArriVent BioPharma, Inc. (AVBP) | United States | $1.485B | -10.25 |
| Xencor Inc (XNCR) | United States | $1.776B | -7.33 |
| Septerna, Inc. (SEPN) | United States | $1.783B | -63.01 |